☰

Todd B. Sherer, PhD - Publications

Affiliations: 
Michael J Fox Foundation 
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, Simuni T. Proposal for a Biologic Staging System of Parkinson's Disease. Journal of Parkinson's Disease. PMID 37066922 DOI: 10.3233/JPD-225111  0.402
2023 Merchant KM, Simuni T, Fedler J, Caspell-Garcia C, Brumm M, Nudelman KNH, Tengstrandt E, Hsieh F, Alcalay RN, Coffey C, Chahine L, Foroud T, Singleton A, Weintraub D, Hutten S, ... Sherer T, et al. LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts. Npj Parkinson's Disease. 9: 30. PMID 36854767 DOI: 10.1038/s41531-023-00468-2  0.351
2022 Frasier M, Fiske BK, Sherer TB. Precision medicine for Parkinson's disease: The subtyping challenge. Frontiers in Aging Neuroscience. 14: 1064057. PMID 36533178 DOI: 10.3389/fnagi.2022.1064057  0.422
2022 Schiess N, Cataldi R, Okun MS, Fothergill-Misbah N, Dorsey ER, Bloem BR, Barretto M, Bhidayasiri R, Brown R, Chishimba L, Chowdhary N, Coslov M, Cubo E, Di Rocco A, Dolhun R, ... ... Sherer T, et al. Six Action Steps to Address Global Disparities in Parkinson Disease: A World Health Organization Priority. Jama Neurology. PMID 35816299 DOI: 10.1001/jamaneurol.2022.1783  0.419
2020 Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107  0.46
2020 Dorsey E, Sherer T, Okun M, Bloem B. The Rise of Parkinson's Disease American Scientist. 108: 176. DOI: 10.1511/2020.108.3.176  0.396
2019 Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, ... ... Sherer T, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 92: 329-337. PMID 30745444 DOI: 10.1212/Wnl.0000000000006926  0.602
2019 Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, ... ... Sherer T, et al. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism & Related Disorders. PMID 30738748 DOI: 10.1016/j.parkreldis.2018.12.025  0.407
2018 Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. Journal of Parkinson's Disease. 8: S3-S8. PMID 30584159 DOI: 10.3233/Jpd-181474  0.305
2018 Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, ... ... Sherer T, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology. 5: 1460-1477. PMID 30564614 DOI: 10.1002/Acn3.644  0.468
2018 Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, ... ... Sherer T, et al. Finding useful biomarkers for Parkinson's disease. Science Translational Medicine. 10. PMID 30111645 DOI: 10.1126/Scitranslmed.Aam6003  0.438
2018 Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, ... ... Sherer T, et al. Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29572948 DOI: 10.1002/Mds.27361  0.386
2016 Sherer TB, Frasier MA, Langston JW, Fiske BK. Parkinson's disease is ready for precision medicine. Personalized Medicine. 13: 405-407. PMID 29767601 DOI: 10.2217/pme-2016-0052  0.389
2015 Dorsey ER, Wagner JD, Bull MT, Rizzieri A, Grischkan J, Achey MA, Sherer T, Chowdhury S, Meunier C, Cappelletti L, Rocker C, Richard IH, Schwarz H, Kang G, Ahmad SH, et al. Feasibility of Virtual Research Visits in Fox Trial Finder. Journal of Parkinson's Disease. 5: 505-15. PMID 26406130 DOI: 10.3233/JPD-150549  0.326
2015 Rocker C, Cappelletti L, Marshall C, Meunier CC, Brooks DW, Sherer T, Chowdhury S. Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder. Journal of Parkinson's Disease. 5: 55-66. PMID 25624422 DOI: 10.3233/JPD-140522  0.356
2014 Jankovic J, Sherer T. The future of research in Parkinson disease Jama Neurology. 71: 1351-1352. PMID 25178587 DOI: 10.1001/jamaneurol.2014.1717  0.311
2014 Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC, Ahmad SO, Sunkin SM, Walker D, Cui X, Fisher DA, McCoy AM, Gamber K, Ding X, ... ... Sherer TB, et al. Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease. Neurobiology of Disease. 70: 190-203. PMID 24969022 DOI: 10.1016/j.nbd.2014.06.009  0.391
2014 Ko WK, Pioli E, Li Q, McGuire S, Dufour A, Sherer TB, Bezard E, Facheris MF. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 772-9. PMID 24610195 DOI: 10.1002/mds.25859  0.385
2013 Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA. A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. Disease Models & Mechanisms. 6: 1316-24. PMID 24046356 DOI: 10.1242/dmm.011940  0.387
2012 Sherer TB, Chowdhury S, Peabody K, Brooks DW. Overcoming obstacles in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1606-11. PMID 23115047 DOI: 10.1002/mds.25260  0.422
2011 Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Sherer T, Frasier M, Meunier C, et al. The Parkinson Progression Marker Initiative (PPMI) Progress in Neurobiology. 95: 629-635. PMID 21930184 DOI: 10.1016/J.Pneurobio.2011.09.005  0.416
2011 Sherer TB. Biomarkers for Parkinson's disease. Science Translational Medicine. 3: 79ps14. PMID 21508309 DOI: 10.1126/scitranslmed.3002488  0.422
2010 Frasier M, Chowdhury S, Eberling J, Sherer T. Biomarkers in Parkinsons disease: A funders perspective Biomarkers in Medicine. 4: 723-729. PMID 20945984 DOI: 10.2217/bmm.10.89  0.315
2009 Dorsey ER, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H. Funding of Parkinson research from industry and US federal and foundation sources. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 731-7. PMID 19133662 DOI: 10.1002/Mds.22446  0.393
2007 Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, Greenamyre JT. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. Journal of Neurochemistry. 100: 1469-79. PMID 17241123 DOI: 10.1111/J.1471-4159.2006.04333.X  0.782
2007 Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, Miller GW. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicological Sciences : An Official Journal of the Society of Toxicology. 95: 196-204. PMID 17038483 DOI: 10.1093/Toxsci/Kfl133  0.708
2006 Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 136-41. PMID 16470786 DOI: 10.1002/mds.20861  0.417
2006 Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiology of Disease. 22: 404-20. PMID 16439141 DOI: 10.1016/J.Nbd.2005.12.003  0.791
2005 Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. The Journal of Biological Chemistry. 280: 42026-35. PMID 16243845 DOI: 10.1074/Jbc.M508628200  0.601
2005 Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicological Sciences : An Official Journal of the Society of Toxicology. 88: 193-201. PMID 16141438 DOI: 10.1093/Toxsci/Kfi304  0.666
2005 Sherer TB, Greenamyre JT. Oxidative damage in Parkinson's disease. Antioxidants & Redox Signaling. 7: 627-9. PMID 15890006 DOI: 10.1089/ars.2005.7.627  0.622
2005 Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Research. Molecular Brain Research. 134: 109-18. PMID 15790535 DOI: 10.1016/J.Molbrainres.2004.11.007  0.739
2005 Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Experimental Neurology. 191: S17-27. PMID 15629758 DOI: 10.1016/J.Expneurol.2004.08.021  0.733
2005 Sherer TB, Betarbet R, Greenamyre JT. Rotenone rat and other neurotoxin models of parkinson disease Movement Disorders. 161-172. DOI: 10.1016/B978-012088382-0/50013-X  0.599
2004 Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, Greenamyre JT, Casida JE. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chemical Research in Toxicology. 17: 1540-8. PMID 15540952 DOI: 10.1021/Tx049867R  0.676
2004 Betarbet R, Poisik O, Sherer TB, Greenamyre JT. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Experimental Neurology. 187: 76-85. PMID 15081590 DOI: 10.1016/J.Expneurol.2003.12.012  0.618
2003 Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 10756-64. PMID 14645467 DOI: 10.1523/Jneurosci.23-34-10756.2003  0.761
2003 Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism & Related Disorders. 9: S59-64. PMID 12915069 DOI: 10.1016/S1353-8020(03)00023-3  0.714
2003 Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience Letters. 341: 87-90. PMID 12686372 DOI: 10.1016/S0304-3940(03)00172-1  0.698
2003 Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Experimental Neurology. 179: 9-16. PMID 12504863 DOI: 10.1006/Exnr.2002.8072  0.714
2002 Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT. Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathology (Zurich, Switzerland). 12: 499-510. PMID 12408237 DOI: 10.1111/J.1750-3639.2002.Tb00468.X  0.748
2002 Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 7006-15. PMID 12177198  0.69
2002 Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinson's disease. The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 8: 192-7. PMID 12061498 DOI: 10.1177/1073858402008003004  0.751
2002 Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 24: 308-18. PMID 11948617 DOI: 10.1002/Bies.10067  0.72
2002 Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage The Journal of Neuroscience. 22: 7006-7015. DOI: 10.1523/Jneurosci.22-16-07006.2002  0.696
2001 Sherer TB, Betarbet R, Greenamyre JT. Pesticides and Parkinson's disease. Thescientificworldjournal. 1: 207-8. PMID 12805673 DOI: 10.1100/Tsw.2001.35  0.713
2001 Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. Iubmb Life. 52: 135-41. PMID 11798025 DOI: 10.1080/15216540152845939  0.723
2001 Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson's disease. Current Opinion in Investigational Drugs (London, England : 2000). 2: 657-62. PMID 11569943  0.719
2001 Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP, Tuttle JB. Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Research. 891: 94-105. PMID 11164812 DOI: 10.1016/S0006-8993(00)03203-0  0.398
2001 Greenamyre JT, Betarbet R, Sherer T, Panov A. Response: Parkinson's disease, pesticides and mitochondrial dysfunction Trends in Neurosciences. 24: 247. DOI: 10.1016/S0166-2236(00)01788-4  0.747
2000 Sherer T, Greenamyre JT. A therapeutic target and biomarker in Friedreich's ataxia. Neurology. 55: 1600-1. PMID 11113210  0.452
2000 Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience. 3: 1301-6. PMID 11100151 DOI: 10.1038/81834  0.788
Show low-probability matches.